Advertisement
| farxiga heart failure study: Therapeutic Strategies for Heart Failure Naoki Sato, 2018-01-24 This book introduces pathophysiology and practical heart failure (HF) management at the acute, in-hospital stages during hospitalization and also in the end-stages of HF. Given its increasing incidence and prevalence, we live in a world that is essentially facing an HF pandemic. A country with an ageing population, Japan is unique in terms of the selection of medical treatment, diagnostic techniques, team managing and other approaches. This book sheds new light on the clinical challenges involved in reducing re-hospitalization and improving patients’ prognosis and ADL/QOL, while also reporting on the status quo in Japan. By highlighting these challenges and the methods used to address them, it will encourage experts around the globe to intensively discuss and accelerate research in this field. Including contributions by authors who have played central roles in managing HF in Japan, the book offers an indispensable guide not only for clinicians, technicians and nurses in this field, but also for general physicians, emergency physicians and all others who are involved in the management of acute and end-stage HF. |
| farxiga heart failure study: Acute Heart Failure Alexandre Mebazaa, Mihai Gheorghiade, Faiez Zannad, Joseph E. Parrillo, 2009-12-24 For many years, there has been a great deal of work done on chronic congestive heart failure while acute heart failure has been considered a difficult to handle and hopeless syndrome. However, in recent years acute heart failure has become a growing area of study and this is the first book to cover extensively the diagnosis and management of this complex condition. The book reflects the considerable amounts of new data reported and many new concepts which have been proposed in the last 3-4 years looking at the epidemiology, diagnostic and treatment of acute heart failure. |
| farxiga heart failure study: Ventricular Arrhythmia Samuel C. Dudley, Ali A. Sovari, Abraham G. Kocheril, 2013 Ventricular arrhythmias are the main cause of sudden arrhythmic death, a devastating situation that is tied to heart failure and its incidence is increasing despite current available therapies. This book reviews and explores the pathophysiology of ventricular arrhythmia and currently available therapeutic modalities including ion channel blockades, catheter ablation and defibrillators, with the hope that the wealth of accumulated science and knowledge have grown to the point that with the help of current advanced technology which allows targeting cellular, molecular and genetic components, a paradigm shift in treatment of these deadliest arrhythmias becomes possible. The book also provides chapters on currently available pharmacological options, defibrillation and catheter ablation as well as chapters on new treatments and technologies such as cell and gene therapies and what may be the future of arrhythmia therapy. |
| farxiga heart failure study: Practical Diabetes Care David Levy, 2017-12-08 Winner in the Internal Medicine category at the 2019 British Medical Association awards. Concise, affordable and extremely practical, Practical Diabetes Care, 4th edition offers a wholly clinical approach to diabetes and its treatment. Covering all the practical aspects of all major aspects of Type 1 and Type 2 diabetes, it also includes the very latest in clinical research and trial results. Structured in a problem-orientated way, the book focuses on the areas of maximum anxiety for health-professionals treating patients with diabetes, e.g. hyperglycaemic emergencies, and multiple complications. Easy to navigate, clear and convenient for when on the wards and in clinic, this is the perfect guide to the practical aspects of caring for patients with diabetes. |
| farxiga heart failure study: Pericardial Disease J. Soler-Soler, G. Permanyer, J. Sagristà-Sauleda, 2012-12-06 In November 1986, I was invited to attend a symposium held in Barcelona on Diseases of the Pericardium. The course was directed by Dr. J. Soler-Soler, director of Cardiology at Hospital General Vall d'Hebron in Barcelona. During my brief but delightful visit to this institution, my appreciation of the depth and breadth of study into pericardial diseases, carried out by Dr. Soler and his group, grew into the conviction that these clinical investigators have accumulated a wealth of information concerning pericardial diseases, and that investigators and clinicians practicing in English speaking countries would greatly profit from ready access to the results of the clinical investiga tions into pericardial disease carried out in Barcelona. The proceedings of the Barcelona conference were published in a beauti fully executed volume in the Spanish language edited by Dr. Soler and pro duced by Ediciones Doyma. Because I believe that this work should be brought to the attention of the English speaking scientific and clinical com munities, I encouraged Dr. Soler to have the book translated into English. I knew that this task could be accomplished and that the book would be trans lated into good English without change of its content. My confidence was based upon a translation of my own book, The Pericardium, into Spanish undertaken by Dr. Permanyer, who is a contributor and co-editor of the pre sent volume. |
| farxiga heart failure study: Frequently Prescribed Medications Michael Mancano, Jason Gallagher, 2010-11-12 Health Sciences & Professions |
| farxiga heart failure study: Understanding Racial and Ethnic Differences in Health in Late Life National Research Council, Division of Behavioral and Social Sciences and Education, Committee on Population, Panel on Race, Ethnicity, and Health in Later Life, 2004-09-08 As the population of older Americans grows, it is becoming more racially and ethnically diverse. Differences in health by racial and ethnic status could be increasingly consequential for health policy and programs. Such differences are not simply a matter of education or ability to pay for health care. For instance, Asian Americans and Hispanics appear to be in better health, on a number of indicators, than White Americans, despite, on average, lower socioeconomic status. The reasons are complex, including possible roles for such factors as selective migration, risk behaviors, exposure to various stressors, patient attitudes, and geographic variation in health care. This volume, produced by a multidisciplinary panel, considers such possible explanations for racial and ethnic health differentials within an integrated framework. It provides a concise summary of available research and lays out a research agenda to address the many uncertainties in current knowledge. It recommends, for instance, looking at health differentials across the life course and deciphering the links between factors presumably producing differentials and biopsychosocial mechanisms that lead to impaired health. |
| farxiga heart failure study: Textbook of Cardiorenal Medicine Peter A. McCullough, Claudio Ronco, 2020-11-24 This textbook provides a practical and board-driven resource to describe and define the emerging field of cardiorenal medicine. Covering all aspects of the topic with depth and relevance, this groundbreaking reference brings together experts at the nexus between cardiovascular and renal medicine to provide an exception reference to educate in this critical area of modern medicine. It describes how the heart and kidneys are inextricably linked via hemodynamic, neural, hormonal and cellular signaling systems and, concentrating on disease-based coverage, goes on to review emerging concepts in epidemiology, pathogenesis, screening, diagnosis and the management of cardiorenal syndromes, all extensively illustrated and containing features to support scholarship in the field. Textbook of Cardiorenal Medicine provides consistent chapter organization, clear design and engaging text to define the diagnosis, treatment, intervention and surgical aspects of the full range of conditions encountered within this area of medicine. It is therefore an essential resource to all involved in the management of cardiorenal disease. |
| farxiga heart failure study: Hepatotoxicity Hyman J. Zimmerman, 1999 Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury. |
| farxiga heart failure study: Handbook of Diabetes Rudy Bilous, Richard Donnelly, Iskandar Idris, 2021-04-29 HANDBOOK OF DIABETES The Handbook of Diabetes provides concise and efficient coverage of the diagnosis, epidemiology, and management of diabetes and its complications. Containing hundreds of attractive colour diagrams, illustrations, and clinical photographs, this popular quick-reference guide focuses on the management and measurement of diabetes mellitus with highly visual references. Now in its fifth edition, this market-leading book aligns with the most recent guidelines from the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), Diabetes UK, and the National Institute for Health and Care Excellence (NICE), presenting authoritative clinical coverage of diabetes in an accessible format with rich pedagogical features. Five new chapters provide detailed coverage of liver disease, diabetes education, bariatric surgery, diabetes and cancer, and the use of incretin-based therapies and SGLT2 Inhibitors in the management of Type II diabetes Updated and expanded topics include the relation between hypoglycaemia and dementia, anxiety and depression, the NICE Quality and Outcomes Framework (QOF), and the impacts of diabetes to self-care, mental health, and decision-making Provides a wealth of pedagogical features such as vignettes and case histories, important learning points, summaries of key clinical trials, and links to further readings Handbook of Diabetes, remains the essential practical companion for all health professionals involved in managing patients with diabetes, and an up-to-date reference for diabetes and endocrinology researchers, scientists, and academics. |
| farxiga heart failure study: Incretin Based Therapies Sanjay Kalra, Rakesh Sahay, Ambika G Unnikrishnan, 2013-03-31 Incretins are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from cells in the pancreas after eating. Incretin based drugs are used to control blood sugar levels in the management of diabetes. This book is a concise guide to incretin based therapy. Beginning with an introduction to the history and physiology of incretins, the following sections examine the clinical pharmacology of GLP-1 Analogues and DPP-4 Inhibitors, the pleiotrophic effects of incretins and comparative pharmacology. Each section integrates science with practical therapeutic guidance for clinicians involved in the management of diabetes. The final chapter discusses the future of incretin therapies, including non-diabetic usage and combination therapy. Key Features Concise overview of incretin based therapy for the management of diabetes Guides clinicians step by step through the history and pharmacology of various molecules Integrates science with practical therapeutic guidance Includes chapter on the future of incretin therapy |
| farxiga heart failure study: Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome Debasis Bagchi, Sreejayan Nair, 2012-01-31 Diabetes mellitus affects approximately 20 million people in the US, or nearly 7% of the population. It is expected to increase by 70% within the next 25 years, and numerous epidemiologic studies have demonstrated that type 2 diabetes increases the risk of cardiovascular morbidity and mortality. It is estimated to cost over $92 billion in health care costs and lost productivity. The increased risk is due to the detrimental vascular effects of prolonged exposure to a hyperglycemic, oxidant-rich environment yielding associated cardiovascular risk factors: atherosclerosis, hypertension and clotting abnormalities. Hypertension and dyslipidemia in diabetic patients produces substantial decreases in cardiovascular and microvascular diseases. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome provides an overview of the current epidemic, outlines the consequences of this crisis and lays out strategies to forestall and prevent diabetes, obesity and other intricate issues of metabolic syndrome. The contributing experts from around the world give this book relevant and up-to-date global approaches to the critical consequences of metabolic syndrome and make it an important reference for those working with the treatment, evaluation or public health planning for the effects of metabolic syndrome and diabetes. Scientific discussion of the epidemiology and pathophysiology of the relationship between diabetes and metabolic syndrome Includes coverage of Pre-diabetes conditions plus both Type I and Type II Diabetes Presents both prevention and treatment options |
| farxiga heart failure study: Managing Heart Failure in Primary Care: A Case Study Approach K. Melissa Smith Hayes, Nicole R. Dellise, 2023-03-29 This guide provides a clear and concise overview of heart failure for primary care clinicians. Written by two nurse practitioners for nurses, nurse practitioners, physician assistants, medical students, and pharmacists, it is uniquely designed to bridge the gap between cardiology and primary care. It delivers the most current recommendations outlined by the American Heart Association and the Heart Failure Society of America guidelines for the management and treatment of heart failure. This book includes a comprehensive overview of heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. Special chapters are dedicated to physical exam, interpretation and application of diagnostic testing, and the management of chronic illness in the setting of acute and chronic heart failure. Additionally, the book provides clinicians with guidance on common medications to avoid, patient education, successful transitions of care, and conversations regarding goals of care. Each chapter includes an overview and learning objectives. The “Practice Pearls” and case studies found throughout the text highlight key takeaway points. |
| farxiga heart failure study: FDA's Drug Review Process and the Package Label Tom Brody, 2017-12-01 FDA's Drug Review Process and the Package Label provides guidance to pharmaceutical companies for writing FDA-submissions, such as the NDA, BLA, Clinical Study Reports, and Investigator's Brochures. The book provides guidance to medical writers for drafting FDA-submissions in a way more likely to persuade FDA reviewers to grant approval of the drug. In detail, the book reproduces data on efficacy and safety from one hundred different FDA-submissions (NDAs, BLAs). The book reproduces comments and complaints from FDA reviewers regarding data that are fragmentary, ambiguous, or that detract from the drug's approvability, and the book reveals how sponsors overcame FDA's concerns and how sponsors succeeded in persuading FDA to grant approval of the drug. The book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely text and data from NDAs and BLAs, as published on FDA's website. The source material for writing this book included about 80,000 pages from FDA's Medical Reviews, FDA's Clinical Pharmacology Reviews, and FDA's Pharmacology Reviews, from one hundred different NDAs or BLAs for one hundred different drugs. Each chapter focuses on a different section of the package label, e.g., the Dosage and Administration section or the Drug Interactions section, and demonstrates how the sponsor's data supported that section of the package label. - Reveals strategies for winning FDA approval and for drafting the package label - Examples are from one hundred FDA-submissions (NDAs, BLAs) for one hundred different drugs, e.g., for oncology, metabolic diseases, autoimmune diseases, and neurological diseases - This book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely, the data from NDAs and BLAs as published on FDA's website at the time FDA grants approval to the drug |
| farxiga heart failure study: Heart Failure Marvin A. Konstam, 1994 |
| farxiga heart failure study: Stroke-Vascular Diseases W.Wolfgang Fleischhacker, David J. Brooks, 2002-11-07 Atherosclerosis, the underlying cause of heart attacks, strokes and peripheral vascular disease, is one of the major killers in the world. By 2020 WHO statistics indicate that it will be the most common cause of morbidity and mortality in both the industrialised world and the underdeveloped world. The disease develops slowly over many years in the innermost layer of large and medium-sized arteries (Fig. 1) (Scott, 1995; Ross, 1999; Naumova and Scott, 2000; Glass and Witztum, 2001; Libby, 2001). It does not usually become manifest before the fourth of fifth decade, but then often strikes with devas tating suddenness. Fifty per cent of individuals still die (25 per cent immedi ately) from their first heart attack; and morbidity from coronary heart disease and stroke is very significant. The disease has a profound impact on health care services and on industrial economies. The lesions of atherosclerosis Autopsy studies show that in humans atherosclerosis begins in the first and second decade of life. A similar disease can be produced in experimental animals, where diet and genetics can be manipulated to produce identical lesions. The earliest lesions are fatty streaks. These consist of an accumulation of lipid-engorged macrophages (foam cells) and T and B lymphocytes in the arterial intima. With time, the fatty streaks progress to intermediate lesions, composed of foam cells and smooth muscle cells. |
| farxiga heart failure study: Comprehensive Cardiovascular Medicine in the Primary Care Setting Peter P. Toth, Christopher P. Cannon, 2010-07-28 Comprehensive Cardiovascular Medicine in the Primary Care Setting provides an authoritative, detailed discussion of cardiovascular disease balanced with practical utility. Disease states are explained with emphasis on risk factors, risk estimation, and established cardiac disease. The book also delves into the co-morbid conditions which surround cardiovascular disease, including peripheral vascular disease, chronic kidney disease, depression, and erectile dysfunction, with the goal of improving quality of life for affected individuals. An abundance of algorithms, case studies, and recommendations on evidence-based best practices facilitate rapid learning. A key resource for the busy practitioner, this book is designed to give the reader the skills to confidently perform assessments, initiate and maintain efficacious therapy, and know when a referral to a cardiologist is advisable. |
| farxiga heart failure study: Endocrine Disorders in Kidney Disease Connie M. Rhee, Kamyar Kalantar-Zadeh, Gregory A. Brent, 2019-03-13 This comprehensive book examines the complex interplay between endocrine and kidney disorders, and how this inter-relationship impacts patients with chronic kidney disease. Authored by experts in areas of endocrinology and nephrology, chapters cover a variety of topics, including diabetes, metabolic syndrome, thyroid dysfunction, gonadal disorders, dyslipidemia, mineral bone disorders, obesity, and pituitary disorders. These comorbidities are thoroughly examined and provide the clinician, researcher, and trainee with a greater understanding of the impact of endocrine disorders on kidney disease patients, the ability to identify persistent gaps in knowledge for future investigation, and move closer towards the goal of improving the health and survival of the chronic kidney disease population. |
| farxiga heart failure study: A Prioritized Research Agenda for Prevention and Control of Noncommunicable Diseases World Health Organization, 2011 Accompanying CD-ROM contains working papers, reports of meetings to develop the prioritized NCD research agenda (2008-2010), lists of participants, list of other contributors and institutions that participated and research priorities for cardiovascular disease prevention and control. |
| farxiga heart failure study: Diabetic Emergencies Nikolaos Katsilambros, Christina Kanaka-Gantenbein, Stavros Liatis, Konstantinos Makrilakis, Nicholas Tentolouris, 2011-09-07 The book explores both the clinical presentation of serious diabetic emergencies (like ketoacidosis, hyperosmolar coma, and severe hyper and hypoglycemia) that consultants and hospital staff encounter in practice and the best methods of both managing the emergencies and also administering follow-up guidance/care. All chapters are clearly structured to highlight: definition of emergency; epidemiology; potential causes, diagnosis, clinical management (including problem areas), follow-up management/care; and patient advice. There are case studies to aid clinical understanding, as well as 5-7 multiple choice questions and several key points/take-home message boxes in every chapter. |
| farxiga heart failure study: From Hypertension to Heart Failure Michael Böhm, John H. Laragh, Manfred Zehender, 2012-12-06 Arterial hypertension, coronary heart disease and heart fail ure are the commonest cardiovascular conditions to present in clinical practice. Over the past few years it has become in creasingly clear that they are closely and causally interrelated and that their relationship can have a significant bearing on prognosis. Epidemiological studies have shown that arterial hypertension is one of the most important risk factors for de veloping heart failure. Only one in four patients with hyper tension is adequately managed, and in 50% of cases, the hypertension has not been recognised or treated. Patients with pre-existing hypertension who go on to suffer an acute myocardial infarction have usually not previously had typi cal angina symptoms, the infarct territory is larger, life threatening arrhythmias are commoner and hence in-hospi tal mortality and long-term prognosis are markedly worse. The presence of raised blood pressure in the post-infarct phase doubles the risk of manifest heart failure. The close relationship between hypertension, coronary heart disease and heart failure makes the choice of therapeu tic strategy particularly important. Agents and classes of agents that have prognostic value in all three conditions should be considered first, as synergy might result in addi tional benefits. In such patients, this sort of therapeutic deci sion-making might have further advantages. The use of these agents may prevent complications which are not yet clinically obvious (such as heart failure). |
| farxiga heart failure study: Synopsis of Neurology, Psychiatry and Related Systemic Disorders Alan B. Ettinger, Deborah M. Weisbrot, Casey E. Gallimore, 2019-05-31 Symptoms and signs in neurology and psychiatry typically present in the clinical context of other underlying conditions. When evaluating a patient, a physician may choose to review a diverse list of potential underlying diagnoses with the aid of the editor team's existing text: Neurological Differential Diagnosis: A Case-Based Approach. However, if the patient has a known pre-existing condition, the physician will need to consider a reverse approach - considering what complications of that condition may be associated with current symptoms. This book provides quick-reference, comprehensive, concise summaries of neurologic, psychiatric and medical diagnoses with a focus on neurologic and psychiatric implications of systemic disorders. A separate pharmacology section provides a consolidated review of potential neurologic and psychiatric adverse effects of medications. This book is an invaluable resource for a broad medical audience, from the medical student to the experienced consultant. |
| farxiga heart failure study: Global Perspectives on Childhood Obesity Debasis Bagchi, 2010-10-12 Understanding the complex factors contributing to the growing childhood obesity epidemic is vital not only for the improved health of the world's future generations, but for the healthcare system. The impact of childhood obesity reaches beyond the individual family and into the public arenas of social systems and government policy and programs. Global Perspectives on Childhood Obesity explores these with an approach that considers the current state of childhood obesity around the world as well as future projections, the most highly cited factors contributing to childhood obesity, what it means for the future both for children and society, and suggestions for steps to address and potentially prevent childhood obesity. - This book will cover the multi-faceted factors contributing to the rapidly growing childhood obesity epidemic - The underlying causes and current status of rapidly growing obesity epidemic in children in the global scenario will be discussed - The strategies for childhood obesity prevention and treatment such as physical activity and exercise, personalized nutrition plans and school and community involvement will be presented |
| farxiga heart failure study: Obesity and Cardiovascular Disease Malcolm K Robinson, Abraham Thomas, 2006-03-07 Although cardiovascular disease remains the leading proximate cause of death in the United States, it is now estimated that obesity may be equivalent to smoking as the leading cause of preventable death in America. In light of these statistics, this reference presents our current understanding of the epidemiology, pathology, and genetics of the obe |
| farxiga heart failure study: Ferri's Clinical Advisor 2021 Fred F. Ferri, 2020-06-10 Find fast answers to inform your daily diagnosis and treatment decisions! Ferri’s Clinical Advisor 2021 uses the popular 5 books in 1 format to deliver vast amounts of information in a clinically relevant, user-friendly manner. This bestselling reference has been significantly updated to provide you with easy access to answers on 1,000 common medical conditions, including diseases and disorders, differential diagnoses, clinical algorithms, laboratory tests, and clinical practice guidelines—all carefully reviewed by experts in key clinical fields. Extensive algorithms, along with hundreds of new figures and tables, ensure that you stay current with today's medical practice. Contains significant updates throughout, covering all aspects of current diagnosis and treatment. Features 27 all-new topics including chronic rhinosinusitis, subclinical brain infarction, reflux-cough syndrome, radiation pneumonitis, catatonia, end-stage renal disease, and genitourinary syndrome of menopause, among others. Includes new appendices covering common herbs in integrated medicine and herbal activities against pain and chronic diseases; palliative care; and preoperative evaluation. Offers online access to Patient Teaching Guides in both English and Spanish. |
| farxiga heart failure study: ASPC Manual of Preventive Cardiology Ezra A. Amsterdam, Nathan Wong, Ezra Amsterdam, MD, Roger Blumenthal, MD, FACC, FAHA, 2014-10-23 Endorsed by the American Society for Preventive Cardiology, this highly practical resource focuses on the application of current guidelines and practice standards in the clinical management of cardiovascular risk factors. The Manual presents concise descriptions of each major cardiovascular risk factor, and practical, to-the-point discussions of current best practices in clinical management. In addition, the Manual includes chapters on peripheral arterial disease, stroke, smoking, contemporary cardiovascular imaging, heart failure, metabolic syndrome, thrombosis, nutrition, special populations, novel risk factors, and psychosocial stress. Throughout the Manual, recommendations are based on the most recent prevention guidelines of the American College of Cardiology and American Heart Association, including those on Risk Assessment, Lifestyle Recommendations, Blood Cholesterol, and Obesity, as well as the new guidelines on Hypertension. Chapter authors are recognized leaders in each area of practice, and special efforts have been made by the authors and editors to ensure that the content of all chapters is as up-to-date as possible. Key Features: Presents a highly practical focus on the application of current guidelines and practice standards regarding cardiovascular risk factors Recommendations based on the most recent prevention guidelines Authored by recognized leaders in the field Covers all major cardiovascular risk factors, key methodologies in risk assessment, and special issues regarding specific patient populations |
| farxiga heart failure study: Polycystic Ovary Syndrome Andrea Dunaif, R. Jeffrey Chang, Stephen Franks, Richard S. Legro, 2008-01-12 This volume includes the latest diagnostic criteria for PCOS and comprises the most up-to-date information about the genetic features and pathogenesis of PCOS. It critically reviews the methodological approaches and the evidence for various PCOS susceptibility genes. The book also discusses additional familial phenotypes of PCOS and their potential genetic basis. All four editors of this title are extremely prominent in the field of PCOS. |
| farxiga heart failure study: The Diabetic Kidney Pedro Cortes, 2007-11-06 A comprehensive and authoritative survey of recent findings, ideas, and hypotheses about the causes and treatment of diabetic nephropathy. The authors cover both the basic pathogenic mechanisms of the disease, as well as many of its clinical aspects of identification, management, and new therapeutic approaches. Highlights include an entire section devoted to novel approaches to studying diabetic nephropathy with the most advanced molecular techniques, and complete descriptions of the most up-to-date views on the diagnosis and treatment of the disease. The Diabetic Kidney offers both researchers and practicing clinicians a clear understanding of the of the progress that has been made regarding the pathogenesis of diabetic nephropathy and of the therapeutic interventions needed to prevent its development or treat it. |
| farxiga heart failure study: Cardiorespiratory Fitness in Cardiometabolic Diseases Peter Kokkinos, Puneet Narayan, 2019-03-18 This book examines the links between physical activity (PA), cardiorespiratory fitness (CRF), and cardiovascular and metabolic diseases. It presents an overview of the role of PA and CRF in the prevention and management of risk factors associated with cardiometabolic diseases such as hypertension, peripheral vascular disease, stroke, type 2 diabetes, metabolic syndrome, dyslipidemia, obesity, and atherosclerosis. In addition, it explores how these risks vary with different populations such as the elderly and people of various racial backgrounds. The book also highlights risks associated with exercise and presents a prescription for appropriate and efficacious exercise to minimize risk and maximize health benefits for the heart. Cardiorespiratory Fitness in Prevention and Management of Cardiometabolic Disease is an essential resource for physicians, exercise physiologists, medical students, residents, fellows, nurses, and researchers in cardiology, cardiorespiratory fitness, exercise science, health promotion and disease prevention, public health, and epidemiology. |
| farxiga heart failure study: Medical Pharmacology and Therapeutics E-Book Derek G. Waller, Tony Sampson, 2013-08-07 This book covers all the pharmacology you need, from basic science pharmacology and pathophysiology, through to clinical pharmacology to therapeutics, in line with the integrated approach of new medical curricula. The first section covers the basic principles, and the rest is organised by body systems. The book ends with sections on toxicity and prescribing practice. Integrates basic science pharmacology, clinical pharmacology and therapeutics Brief review of pathophysiology of major diseases Case histories and multiple choice questions (and answers) Tabular presentation of all common drugs within each class Section on further reading Kinetics chapter simplified with more practical examples Includes more on genetic issues Drug tables made more concise to make information more accessible Fully updated to reflect current clinical practice |
| farxiga heart failure study: Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases Solomon Habtemariam, 2019-06-08 Medicinal Foods as Potential Therapies for Type-2 Diabetes and Associated Diseases: The Chemical and Pharmacological Basis of their Action focuses on active pharmacological principles that modulate diabetes, associated risk factors, complications and the mechanism of action of widely used anti-diabetic herbal plants—rather than just the nutritional composition of certain foods. The book provides up-to-date information on acclaimed antidiabetic super fruits, spices and other food ingredients. Sections cover diabetes and obesity at the global level, the physiological control of carbohydrate and lipid metabolism, the pathophysiology of type-2 diabetes, the chemistry and pharmacology of a variety of spices, and much more. This book will be invaluable for research scientists and students in the medical and pharmaceutical sciences, medicinal chemistry, herbal medicine, drug discovery/development, nutrition science, and for herbal practitioners and those from the nutraceutical and pharm industries. - Provides background knowledge on type-2 diabetes and its pathophysiology and therapeutic targets down to the molecular level - Explores, in detail, the chemistry or secondary metabolites of the indicated foods that potentially modify diabetes and/or associated diseases - Examines the pharmacological findings on medicinal foods, including available clinical trials |
| farxiga heart failure study: Manual for Pharmacy Technicians Bonnie S. Bachenheimer, 2019-08-15 The Trusted Training Resource for Pharmacy Technicians at All Levels The role of pharmacy technicians is rapidly expanding, and demand for well-trained technicians has never been higher! Technicians are assuming more responsibilities and are taking on greater leadership roles. Quality training material is increasingly important for new technicians entering the field, and current technicians looking to advance. Look no further than the new 5th edition of the best-selling Manual for Pharmacy Technicians to master the practical skills and gain the foundational knowledge all technicians need to be successful. |
| farxiga heart failure study: Emergency Cardiology Second Edition Karim Ratib, Gurbir Bhatia, Neal Uren, James Nolan, 2010-11-26 This fully revised and updated second edition of Emergency Cardiology offers highly practical advice on the diagnosis and management of acute cardiac conditions. Throughout the book the authors employ an evidence-based approach to clinical practice, and provide detailed guidance for day-to-day practice in a wider variety of settings - from the emergency department to intensive care and the cardiac ward. Provides essential advice for the rapid diagnosis and management of cardiac emergencies - both common and more rare. Includes evidence-based guidelines and the results of the most groundbreaking clinical trials Practical format pocket-sized format Authored by four cardiologists with extensive experience in the emergency setting Emergency Cardiology, Second Edition is an essential purchase for junior doctors, emergency department staff, trainees in cardiology and specialist nurses. |
| farxiga heart failure study: Diastology E-Book Allan L. Klein, Mario J. Garcia, 2020-10-24 Accounting for more than 40% of all heart failure problems, diastolic heart failure is a complex and often difficult diagnosis with rapidly evolving diagnostic management protocols. Diastology: Clinical Approach to Heart Failure with Preserved Ejection Fraction, 2nd Edition, brings you up to date and equips you to successfully diagnose and manage even the most challenging incidences of diastolic heart failure and their comorbidities. It incorporates the latest guidelines for the diagnostic evaluation of the patient with suspected or known diastolic dysfunction, provides a comprehensive review of clinical conditions associated with heart failure with preserved ejection fraction, and describes the complementary role of imaging modalities and novel therapeutic approaches. - Keeps you current with recent extensive changes in the understanding of the mechanisms of diastolic heart failure with preserved ejection fraction (HFpEF) that have resulted in dramatic changes in treatment guidelines. - Covers the latest molecular, genetic, and cellular mechanisms behind diastolic heart failure as a basis for the latest clinical approaches, diagnosis, and treatment of common and uncommon pathological conditions such as hypertensive heart disease, cardiomyopathies, arterial and valvular diseases, pericardial diseases, congenital heart disease, diabetes mellitus, and metabolic syndrome. - Features 50 video cases, new key summary points, new multiple-choice review questions, and six new chapters: Evaluation of Diastolic Function by Radionuclide Techniques; Diastology Stress Test; ASE/EACVI Diastolic Guidelines; Valve Disease; Perioperative Assessment of Diastolic Dysfunction; and Pulmonary Hypertension. - Reviews new techniques and indices for assessing diastolic function, such as 3D echo, strain rate imaging, late gadolinium enhancement and T1-mapping by CMR, and novel nuclear scintigraphic methods – as well as the traditional indices of LV filling, LA function, and tissue Doppler indices. - Covers emerging topics such as the role of neurohormones, global and regional systolic function of the left ventricle, chronotopic incompetence and pacing, aging, perioperative assessment, and more. - Presents information in a quick-retrieval format, covering Epidemiology, Pathophysiology, Diagnostic Evaluation, Differential Diagnosis, Treatment, and Future Directions. - Helps you learn efficiently and prepare for self-assessment with key summaries and multiple-choice questions and answers for each chapter. |
| farxiga heart failure study: Diabetic Retinopathy and Cardiovascular Disease C. Sabanayagam, T.Y. Wong, 2019-06-03 Diabetic retinopathy (DR), a common microvascular complication, has consistently been shown to be associated with an increased risk of cardiovascular disease (CVD). This book provides complete coverage of DR as a potential marker for CVD in those with diabetes. It succinctly reviews the epidemiological and pathogenic links of DR to various cardiovascular events including stroke, coronary artery disease, chronic kidney disease, heart failure, and mortality. Furthermore, it discusses the usefulness of DR in CVD risk prediction and cardiovascular safety of anti-VEGF therapy in diabetic patients. There are insights from contemporary diabetic trials that demonstrated the enhanced cardiovascular benefit of novel glucose lowering therapy. It also highlights the potential of novel retinal imaging to predict CVD and its risk factors using the state-of-the art artificial intelligence-based deep learning systems. This book will be an invaluable resource for specialists translating research findings into clinical care, including those in cardiology, endocrinology, ophthalmology, and general practitioners. IT will also be of interest to public health practitioners, researchers, graduate students, and biotech companies interested in developing retinal image-based diagnostic and prognostic tools. |
| farxiga heart failure study: Obesity and Cardiovascular Disease Gianluca Iacobellis, 2009-10-08 This essential book comprehensively covers the diagnosis, treatment and management of cardiovascular disease in obese patients, translating up-to-date clinical research findings into clinical practice. |
| farxiga heart failure study: Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure Mukesh Nandave, |
| farxiga heart failure study: Encyclopedia of Dietary Supplements Paul M. Coates, Joseph M. Betz, Marc R. Blackman, Gordon M. Cragg, Mark Levine, Joel Moss, Jeffrey D. White, 2010-06-25 Encyclopedia of Dietary Supplements presents peer-reviewed, objective entries that rigorously examine the most significant scientific research on basic chemical, preclinical, and clinical data. Designed for healthcare professionals, researchers, and health-conscious consumers, it presents evidence-based information on the major vitamin and mineral micronutrients, herbs, botanicals, phytochemicals, and other bioactive preparations. Supplements covered include: Vitamins, beta-carotene, niacin, and folate Omega-3 and omega-6 fatty acids, isoflavones, and quercetin Calcium, copper, iron, and phosphorus 5-hydroxytryptophan, glutamine, and L-arginine St. John's Wort, ginkgo biloba, green tea, kava, and noni Androstenedione, DHEA, and melatonin Coenzyme Q10 and S-adenosylmethionine Shiitake, maitake, reishi, and cordiceps With nearly 100 entries contributed by renowned subject-specific experts, the book serves as a scientific checkpoint for the many OTC supplements carried in today's nutritional products marketplace. Also Available OnlineThis Taylor & Francis encyclopedia is also available through online subscription, offering a variety of extra benefits for researchers, students, and librarians, including: Citation tracking and alerts Active reference linking Saved searches and marked lists HTML and PDF format options Contact Taylor and Francis for more information or to inquire about subscription options and print/online combination packages. US: (Tel) 1.888.318.2367; (E-mail) e-reference@taylorandfrancis.com International: (Tel) +44 (0) 20 7017 6062; (E-mail) online.sales@tandf.co.uk |
| farxiga heart failure study: Type 2 Diabetes in Children and Adolescents Arlan L. Rosenbloom, Janet H. Silverstein, 2003 As a consequence of the obesity epidemic, the prevalence of type 2 diabetes in children and adolescents is increasing. For medical trend watchers and health care professionals alike, this groundbreaking book covers epidemiology of type 2 diabetes in youth; pathophysiology of type 2 in youth; case-finding criteria; early recognition of risk factors; prevention of obesity in this population; and more. |
| farxiga heart failure study: Cardiometabolic Diseases Gundu H. R. Rao, Undurti N. Das, 2024-09-27 Cardiometabolic diseases are a group of metabolic dysfunctions mainly characterized by insulin resistance, impaired glucose tolerance, dyslipidemia, hypertension, and central adiposity that are major contributors to increased risk of acute vascular events such as myocardial infarction, heart failure and stroke. Cardiometabolic Diseases: Molecular Basis, Early Detection of Risks, and Management provides detailed information on all aspects of metabolic dysfunctions and associated risks for cardiometabolic diseases, including a thoughtful discussion of cellular and molecular mechanisms involved in the progression of metabolic risks, the approaches for the early detection and robust management of metabolic risks. Written by a team of expert contributors, this book is useful reading for researchers and clinicians interested on recent advances in etiology of cardiometabolic diseases, the latest noninvasive approaches for diagnosis, risk assessment tools, therapeutic strategies, and also aspects of prevention of cardiometabolic diseases. - Covers all aspects of cardiometabolic diseases, from cellular and molecular mechanisms involved in the development of metabolic risks to clinical practice - Provides established guidelines that facilitate effective management of the independent risk factors that promote vascular diseases - Discusses the use of diagnostic tools to empower patients to self-monitor the progress or regress of modifiable risks |
Farxiga: Uses, Dosage, Side Effects & Warnings - Drugs.com
Sep 2, 2024 · Farxiga can cause the following serious side effects. Diabetic ketoacidosis (increased ketones in your blood or urine) in people with type 1 diabetes and other …
What is Farxiga used for and how does it work? - Drugs.com
May 7, 2025 · Farxiga works in a part of the kidneys called the proximal renal tubule. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. SGLT2 allows glucose to be reabsorbed …
Dapagliflozin: Uses, Dosage, Side Effects, Warnings - Drugs.com
Mar 25, 2025 · Dapagliflozin (Farxiga) is an SGLT2 inhibitor that is mainly used alongside diet and exercise to help treat type 2 diabetes, but it is also used in the treatment of heart failure.
Farxiga Patient Tips: 7 things you should know - Drugs.com
Jun 18, 2024 · Farxiga is not recommended during the second and third trimester of pregnancy and there is a lack of data assessing the risk for the first trimester of pregnancy. However, the …
Farxiga Side Effects: Common, Severe, Long Term - Drugs.com
May 30, 2025 · Farxiga side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal …
Farxiga: Package Insert / Prescribing Information - Drugs.com
FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization …
Farxiga Dosage Guide - Drugs.com
Oct 24, 2024 · The recommended dosage of FARXIGA in patients with an eGFR greater than or equal to 25 mL/min/1.73 m 2 is the same as the recommended dosage in patients with normal …
Farxiga Interactions Checker - Drugs.com
Farxiga Interactions. There are 372 drugs known to interact with Farxiga (dapagliflozin), along with 4 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 2 are …
How long does it take for Farxiga to work? - Drugs.com
Apr 25, 2025 · However, it takes multiple doses of once-daily Farxiga to decrease a patient's blood glucose or sugar levels, meaning that it may take a week for Farxiga to take full effect. In …
Farxiga Reviews & Ratings - Drugs.com
For Type 2 Diabetes "Started taking 10mg Farxiga about 1 year ago, within 1 week I had developed Balanoposthitis (inflammation of the head of the penis), which I seem to now have …
Farxiga: Uses, Dosage, Side Effects & Warnings - Drugs.com
Sep 2, 2024 · Farxiga can cause the following serious side effects. Diabetic ketoacidosis (increased ketones in your blood or urine) in people with type 1 diabetes and other …
What is Farxiga used for and how does it work? - Drugs.com
May 7, 2025 · Farxiga works in a part of the kidneys called the proximal renal tubule. It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. SGLT2 allows glucose to be reabsorbed …
Dapagliflozin: Uses, Dosage, Side Effects, Warnings - Drugs.com
Mar 25, 2025 · Dapagliflozin (Farxiga) is an SGLT2 inhibitor that is mainly used alongside diet and exercise to help treat type 2 diabetes, but it is also used in the treatment of heart failure.
Farxiga Patient Tips: 7 things you should know - Drugs.com
Jun 18, 2024 · Farxiga is not recommended during the second and third trimester of pregnancy and there is a lack of data assessing the risk for the first trimester of pregnancy. However, the …
Farxiga Side Effects: Common, Severe, Long Term - Drugs.com
May 30, 2025 · Farxiga side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal …
Farxiga: Package Insert / Prescribing Information - Drugs.com
FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization …
Farxiga Dosage Guide - Drugs.com
Oct 24, 2024 · The recommended dosage of FARXIGA in patients with an eGFR greater than or equal to 25 mL/min/1.73 m 2 is the same as the recommended dosage in patients with normal …
Farxiga Interactions Checker - Drugs.com
Farxiga Interactions. There are 372 drugs known to interact with Farxiga (dapagliflozin), along with 4 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 2 are …
How long does it take for Farxiga to work? - Drugs.com
Apr 25, 2025 · However, it takes multiple doses of once-daily Farxiga to decrease a patient's blood glucose or sugar levels, meaning that it may take a week for Farxiga to take full effect. In …
Farxiga Reviews & Ratings - Drugs.com
For Type 2 Diabetes "Started taking 10mg Farxiga about 1 year ago, within 1 week I had developed Balanoposthitis (inflammation of the head of the penis), which I seem to now have …
